GLMD logo

Galmed Pharmaceuticals (GLMD) Company Overview

Profile

Full Name:

Galmed Pharmaceuticals Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

March 13, 2014

Indexes:

Not included

Website:

http://www.galmedpharma.com

Description:

Galmed Pharmaceuticals (GLMD) is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH). They aim to improve patient outcomes through innovative therapies, with a strong emphasis on research and clinical trials to bring new medications to market.

Key Details

Price

$2.60

Market Cap

$4.31 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$30.00(+76.53% YoY)

PE Ratio

-

Annual ROE

-49.80%

Annual Debt To Equity

0.00

Beta

1.34

Events Calendar

Earnings

Next earnings date:

May 30, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

May 2, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 30, 2024

Analyst ratings

Recent major analysts updates

Jul 24, 23 Maxim Group
Buy
Aug 8, 22 Maxim Group
Hold
Aug 8, 22 Canaccord Genuity
Hold
May 18, 22 Raymond James
Market Perform
May 3, 22 Raymond James
Outperform
May 3, 22 HC Wainwright & Co.
Neutral
May 17, 21 Canaccord Genuity
Buy
Mar 19, 21 HC Wainwright & Co.
Buy
Jan 8, 21 Raymond James
Outperform
Nov 25, 20 Canaccord Genuity
Buy

Screeners with GLMD included

Growing Shares Outstanding
Stocks with high beta
Stocks below SMA 200
Most recommended stocks
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
Israeli stocks
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.60
GLMD price is $2.60

Price All-time High

$215.52
GLMD price is currently -98.79% below its historical high of $215.52

Price Analysts Target

-
GLMD price consensus analysts' forecast is unknown

Price Today Change

-0.18%
GLMD price is down -0.18% today

Price YTD Change

-15.74%
GLMD price is down -15.74% since January 1st

Price 3-Year Change

-87.24%
GLMD price is down -87.24% over the past 3 years

Market cap

Market Cap

$4.31 M
GLMD market capitalization is $4.31 million

Market Cap 3-Year Change

+51.71%
GLMD market capitalization is up +51.71% over the past 3 years

Market Cap All-time High

$21.31 M
GLMD market capitalization is currently -79.75% below its historical high of $21.31 million

Market Cap Sector Rank

10.62%
GLMD market capitalization is higher than 10.62% of companies in Healthcare sector

Technical

Beta

1.34
GLMD beta is 1.34

200-day SMA

$3.88
GLMD price is currently -32.87% below its 200-day simple moving average

14-day RSI

38.81
GLMD 14-day relative strength index is 38.81

30-day Relative Volume

0.27
GLMD 30-day relative volume is 0.27

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
GLMD annual revenue value is unknown

Annual Revenue Analysts Estimate

-
GLMD annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
GLMD annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
GLMD annual revenue is unknown

Profit

Annual Gross Profit

-
GLMD annual gross profit value is unknown

Annual Gross Margin

-
GLMD annual gross profit margin value is unknown

Annual Operating Profit

-$7.49 M
GLMD annual operating income is -$7.49 million

Annual Operating Margin

-
GLMD annual operating profit margin value is unknown

Annual Net Income

-$6.91 M
GLMD annual net profit is -$6.91 million

Annual Net Margin

-
GLMD annual net profit margin value is unknown

EPS

Annual EPS

-$30.00
GLMD annual earnings per share is -$30.00

Annual EPS Analysts Estimate

-$1.29
GLMD annual earnings per share is currently +2225.58% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+76.53%
GLMD annual earnings per share is up +76.53% year-on-year

Annual EPS Sector Rank

7.57%
GLMD annual earnings per share is higher than 7.57% of companies in Healthcare sector

ROA & ROE

Annual ROA

-41.57%
GLMD annual return on assets is -41.57%

Annual ROE

-49.80%
GLMD annual return on equity is -49.80%

EBIT & EBITDA

Annual EBIT

-$7.49 M
GLMD annual earnings before interest & taxes is -$7.49 million

Annual EBITDA

-$7.46 M
GLMD annual EBITDA is -$7.46 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
GLMD price to earnings ratio value is unknown

PE Ratio Sector Rank

-
GLMD price to earnings ratio is unknown

PB Ratio

PB Ratio

0.23
GLMD price to book ratio is 0.23

PB Ratio Sector Rank

19.53%
GLMD price to book ratio is higher than 19.53% of companies in Healthcare sector

PS Ratio

PS Ratio

-
GLMD price to sales ratio value is unknown

PS Ratio Sector Rank

-
GLMD price to sales ratio is unknown

Enterprise value

Enterprise Value

-$5.41 M
GLMD enterprise value is -$5.41 million

Enterprise Value Sector Rank

5.19%
GLMD enterprise value is higher than 5.19% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.81
GLMD EV/EBITDA is 0.81

EV/EBITDA Sector Rank

75.2%
GLMD EV/EBITDA is higher than 75.2% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.81
GLMD annual current ratio is 4.81

Annual Quick Ratio

-
GLMD annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
GLMD annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
GLMD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
GLMD piotroski f-score value is unknown

Altman Z-Score

-
GLMD altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$16.63 M
GLMD annual total assets is $16.63 million

Annual Non Current Assets

$3.39 M
GLMD annual long term assets is $3.39 million

Annual Current Assets

$13.24 M
GLMD annual total current assets is $13.24 million

Annual Cash & Cash Equivalents

$2.86 M
GLMD annual cash & cash equivalents is $2.86 million

Equity

Annual Book Value

$13.88 M
GLMD annual book value is $13.88 million

Annual Working Capital

$10.49 M
GLMD annual working capital is $10.49 million

Liabilities

Annual Total Liabilities

$2.75 M
GLMD annual total liabilities is $2.75 million

Annual Total Long Term Liabilities

$0.00
GLMD annual total long term liabilities is $0.00

Annual Current Liabilities

$2.75 M
GLMD annual total current liabilities is $2.75 million

Annual Accounts Payable

$1.88 M
GLMD annual accounts payable is $1.88 million

Debt

Annual Total Debt

$41.00 K
GLMD annual total debt is $41.00 thousand

Annual Total Debt 1-Year Change

-80.93%
GLMD annual total debt is down -80.93% year-on-year

Annual Long Term Debt

$0.00
GLMD annual long term debt is $0.00

Annual Short Term Debt

$41.00 K
GLMD annual short term debt is $41.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$7.49 M
GLMD annual total expenses is $7.49 million

Annual Operating Expenses

$7.49 M
GLMD annual total operating expenses is $7.49 million

Annual Cost Of Goods Sold

-
GLMD annual cost of goods sold value is unknown

Annual SGA

$3.92 M
GLMD annual SGA is $3.92 million

Annual D&A

$31.00 K
GLMD annual depreciation & amortization is $31.00 thousand

Annual Interest Expense

-
GLMD annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$6.14 M
GLMD annual cash flow from operations is -$6.14 million

Annual CFO 1-Year Change

+66.83%
GLMD annual cash flow from operations is up +66.83% year-on-year

Annual CFI

$800.00 K
GLMD annual cash flow from investing activities is $800.00 thousand

Annual CFI 1-Year Change

-95.44%
GLMD annual cash flow from investing activities is down -95.44% year-on-year

Annual CFF

$6.18 M
GLMD annual cash flow from financing activities is $6.18 million

Annual CFF 1-Year Change

+8735.71%
GLMD annual cash flow from financing activities is up +8735.71% year-on-year

Free CashFlow

Annual FCF

-$6.14 M
GLMD annual free cash flow is -$6.14 million

Annual FCF 1-Year Change

+66.84%
GLMD annual free cash flow is up +66.84% year-on-year

CAPEX

Annual CAPEX

-
GLMD annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
GLMD annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

ATIP logo
ATI Physical Therapy (ATIP)
GHSI logo
Guardion Health Sciences (GHSI)
EYEN logo
Eyenovia (EYEN)
SNPX logo
Synaptogenix (SNPX)
Polyrizon (PLRZ)
ARTL logo
Artelo Biosciences (ARTL)
GNPX logo
Genprex (GNPX)
Klotho Neuroscience (KLTO)
NCNA logo
NuCana (NCNA)
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
GLMD
prnewswire.comSeptember 25, 2024

The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

Galmed Pharma Surges 400%: What's Behind the Explosion?
Galmed Pharma Surges 400%: What's Behind the Explosion?
Galmed Pharma Surges 400%: What's Behind the Explosion?
GLMD
marketbeat.comSeptember 17, 2024

Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
GLMD
InvestorPlaceJuly 13, 2023

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.

Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
GLMD
InvestorPlaceMay 5, 2023

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.

FAQ

  • What is the ticker symbol for Galmed Pharmaceuticals?
  • Does Galmed Pharmaceuticals pay dividends?
  • What sector is Galmed Pharmaceuticals in?
  • What industry is Galmed Pharmaceuticals in?
  • What country is Galmed Pharmaceuticals based in?
  • When did Galmed Pharmaceuticals go public?
  • Is Galmed Pharmaceuticals in the S&P 500?
  • Is Galmed Pharmaceuticals in the NASDAQ 100?
  • Is Galmed Pharmaceuticals in the Dow Jones?
  • When was Galmed Pharmaceuticals's last earnings report?
  • When does Galmed Pharmaceuticals report earnings?
  • Should I buy Galmed Pharmaceuticals stock now?

What is the ticker symbol for Galmed Pharmaceuticals?

The ticker symbol for Galmed Pharmaceuticals is NASDAQ:GLMD

Does Galmed Pharmaceuticals pay dividends?

No, Galmed Pharmaceuticals does not pay dividends

What sector is Galmed Pharmaceuticals in?

Galmed Pharmaceuticals is in the Healthcare sector

What industry is Galmed Pharmaceuticals in?

Galmed Pharmaceuticals is in the Biotechnology industry

What country is Galmed Pharmaceuticals based in?

Galmed Pharmaceuticals is headquartered in Israel

When did Galmed Pharmaceuticals go public?

Galmed Pharmaceuticals's initial public offering (IPO) was on March 13, 2014

Is Galmed Pharmaceuticals in the S&P 500?

No, Galmed Pharmaceuticals is not included in the S&P 500 index

Is Galmed Pharmaceuticals in the NASDAQ 100?

No, Galmed Pharmaceuticals is not included in the NASDAQ 100 index

Is Galmed Pharmaceuticals in the Dow Jones?

No, Galmed Pharmaceuticals is not included in the Dow Jones index

When was Galmed Pharmaceuticals's last earnings report?

Galmed Pharmaceuticals's most recent earnings report was on Nov 14, 2024

When does Galmed Pharmaceuticals report earnings?

The next expected earnings date for Galmed Pharmaceuticals is May 30, 2025

Should I buy Galmed Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions